- Fresenius Medical Care and CytoSorbents have expanded their
partnership via a multi-stage collaboration designed to seize new
sales opportunities and jointly develop future innovations
- CytoSorb will be featured on Fresenius Medical Care's
critical care platforms for the removal of cytokines, bilirubin,
and myoglobin
- Fresenius Medical Care will be responsible for the specific
worldwide marketing and combined promotion of CytoSorb with its
critical care products utilizing multiple highly visible and
prominent marketing channels and campaigns
- CytoSorbents' proprietary hemoadsorption CytoSorb therapy
expands the dimensions of blood purification of the Fresenius
Medical Care critical care product portfolio
BAD HOMBURG V.D. HÖHE,
GERMANY and PRINCETON, N.J., Aug. 2, 2022
/PRNewswire/ -- Fresenius Medical Care (NYSE: FMS; Frankfurt Stock
Exchange: FME) and CytoSorbents Corporation (NASDAQ: CTSO) have
expanded their partnership by establishing a multi-stage global
collaboration to combat life-threatening diseases in critical care
for an initial term of three years. The new agreement provides for
the combined marketing and promotion of CytoSorb® with
Fresenius Medical Care's critical care products by Fresenius
Medical Care's marketing organization worldwide, excluding
the United States. Compared to the
prior co-marketing agreement, this agreement increases the
commitments from both parties and ensures an ongoing and consistent
level of marketing and promotional activity specifically focused
around CytoSorb, where Fresenius Medical Care will actively market
and promote CytoSorb as the featured blood purification therapy for
removal of cytokines, bilirubin, and myoglobin on its critical care
platforms. Over the next three years, various Fresenius Medical
Care-led in-person, virtual, social media, and web-based marketing
programs and events will feature CytoSorb therapy and highlight the
cooperation between the two companies in the field of critical
care.
Fresenius Medical Care and CytoSorbents
expand global marketing collaboration featuring CytoSorb
"As part of Fresenius Medical Care's commitment to providing our
customers with leading solutions for their critical care patients,
we are pleased to announce this new global collaboration with
CytoSorbents," said Dr. Olaf Schermeier, CEO of Critical Care at
Fresenius Medical Care. "With the ability to seamlessly integrate
CytoSorb with our multiFiltratePRO acute dialysis platform that is
routinely used throughout the world today, we have the opportunity
to positively impact patient care for various life-threatening
conditions such as sepsis, liver failure, trauma, lung injury, and
many others."
Dr. Christian Steiner, Executive
Vice President of Sales and Marketing of CytoSorbents commented,
"CytoSorb adds a powerful new dimension of blood purification to
Fresenius Medical Care's critical care portfolio. It is
specifically designed to reduce toxic levels of cytokines,
bilirubin, and myoglobin that can lead to organ failure. The
process is similar to hemodialysis, mastered by Fresenius Medical
Care to treat kidney failure, which removes accumulated small to
medium-sized, water-soluble molecules and toxins from the
bloodstream. However, CytoSorb adds the ability to remove large
molecules and toxins that are poorly removed by hemodialysis.
Combined, the two therapies work together in a complementary manner
to provide treatment for a broad range of conditions in the
intensive care unit."
Dr. Steiner went on to highlight the importance of this
collaboration stating, "Together with Fresenius Medical Care, we
now have the ability to broadly and consistently communicate the
benefits of CytoSorb therapy to customers throughout the world. In
addition, it enables us to execute targeted marketing campaigns in
collaboration with Fresenius Medical Care which will help to
accelerate the introduction and adoption of CytoSorb. Overall, I
believe this will be the starting point for further exciting
developments on both the medical and business fronts."
Mr. Chris Cramer, Vice President
of Business Development at CytoSorbents commented, "We are excited
to expand our relationship with our long-standing partner,
Fresenius Medical Care. This agreement promotes a stronger
collaboration with Fresenius Medical Care's global commercial
organization to more effectively bring our CytoSorb therapy to more
customers around the world as a featured blood purification
solution on Fresenius Medical Care's critical care platforms.
We believe the synergy has the potential to create sustained and
broader growth for both companies over time and is just the first
of multiple opportunities to offer our combined critical care
solutions."
In addition to strengthening and expanding the global marketing
of CytoSorb, CytoSorbents and Fresenius Medical Care also plan to
work together to bring new innovative solutions to the market. The
agreement also includes the certification of compatibility between
CytoSorb and Fresenius Medical Care's current critical care
platforms. To help support the increased marketing and promotional
efforts of the expanded collaboration, CytoSorbents has agreed to
subsidize a portion of the marketing costs through a royalty
payment to Fresenius Medical Care based on CytoSorb sales in the
intensive care unit on Fresenius Medical Care platforms, excluding
the United States.
About Fresenius Medical Care (NYSE: FMS; Frankfurt Stock
Exchange: FME)
Fresenius Medical Care is the world's
leading provider of products and services for individuals with
renal diseases of which around 3.8 million patients worldwide
regularly undergo dialysis treatment. Through its network of 4,163
dialysis clinics, Fresenius Medical Care provides
dialysis treatments for approximately 346,000 patients around the
globe. Fresenius Medical Care is also the leading
provider of dialysis products such as dialysis machines or
dialyzers. Along with its core business, the Renal Care
Continuum, the Company focuses on expanding in complementary areas
and in the field of critical care. Fresenius Medical
Care is listed on the Frankfurt Stock Exchange (FME)
and on the New York Stock Exchange (FMS).
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in the
treatment of life-threatening conditions in the intensive care unit
and in cardiac surgery through blood purification. Its lead
product, CytoSorb®, is approved in the European Union
and distributed in more than 70 countries worldwide. It is
an extracorporeal cytokine adsorber that reduces
"cytokine storm" or "cytokine release
syndrome" in common critical illnesses that can lead to massive
inflammation, organ failure and patient death. In these
diseases, the risk of death can be extremely high, and there are
few, if any, effective treatments. CytoSorb is
also used during and after cardiothoracic surgery to
remove inflammatory mediators that can lead to postoperative
complications, including multiple organ failure. As of
June 30, 2022, more than
179,000 CytoSorb devices have been used
cumulatively. CytoSorb was originally launched
in the European Union under CE mark as the
first cytokine adsorber. Additional CE
mark extensions were granted for bilirubin
and myoglobin removal in clinical conditions
such as liver disease and trauma, respectively, and for
ticagrelor and rivaroxaban removal in
cardiothoracic surgery procedures. CytoSorb
has also received FDA Emergency Use Authorization
in the United States for use
in adult critically ill COVID-19 patients with impending or
confirmed respiratory failure. The
DrugSorb™-ATR antithrombotic removal system,
based on the same polymer technology as CytoSorb, also
received two FDA Breakthrough Device Designations,
one for the removal of ticagrelor and another for
the removal of the direct oral anticoagulants (DOAC)
apixaban and rivaroxaban in a cardiopulmonary bypass circuit
during urgent cardiothoracic procedures. The
company has initiated two FDA-approved pivotal studies to support
FDA marketing approval of DrugSorb-ATR in the United
States. The first is the randomized, controlled STAR-T
(Safe and Timely Antithrombotic
Removal-Ticagrelor) study of 120 patients at 30 centers to
evaluate whether intraoperative use of
DrugSorb-ATR can reduce the perioperative risk
of bleeding in patients receiving ticagrelor and
undergoing cardiothoracic surgery. The second
study is the STAR‑D (Safe and Timely Antithrombotic
Removal-Direct Oral Anticoagulants) randomized, controlled
trial of 120 patients at 30 centers evaluating the
intraoperative use of DrugSorb-ATR to
reduce perioperative bleeding risk in patients
undergoing cardiothoracic surgery and taking direct
oral anticoagulants, including apixaban and
rivaroxaban.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other body fluids through pore
entrapment and surface adsorption. The company's technologies
have received more than $39.5 million
in non-dilutive grants, contracts and other non-dilutive funding
from DARPA, the U.S. Department of Health and Human Services (HHS),
the National Institutes of Health (NIH), the National Heart, Lung,
and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force,
U.S. Special Operations Command (SOCOM), Air Force Material Command
(USAF/AFMC) and others. The company has numerous marketed and
in-development products based on this unique blood purification
technology protected by numerous issued U.S. and international
patents and registered trademarks, as well as several pending
patent applications, including ECOS-300CY®, CytoSorb-XL™,
HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™,
DrugSorb™, DrugSorb™-ATR, ContrastSorb and others. For more
information, please visit the company's websites at
www.cytosorbents.com and www.cytosorb.com or follow us on Facebook
and Twitter.
Forward-looking statements
This press release
contains forward-looking statements that fall within the safe
harbor of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to,
statements regarding our plans, objectives, future goals and
prospects for our business, expectations regarding the future
impact of COVID-19 or the ongoing conflict between Russia and Ukraine, representations and assertions, and
are not historical facts and are generally identified by the use of
words such as "may," "should," "could," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential,"
"continue" and similar terms, although some forward-looking
statements are worded differently. You should be aware that the
forward-looking statements in this press release reflect
management's current beliefs and expectations, but that our actual
results, events and performance may differ materially from those in
the forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, the
risks disclosed in our Annual Report on Form 10-K filed with the
SEC on March 10, 2022, our Quarterly
Reports on Form 10-Q and the press releases and other
communications to stockholders that we issue from time to time
seeking to inform interested parties of the risks and factors that
may affect our business. We caution you not to place undue reliance
on such forward-looking statements. We are under no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except
as required by federal securities laws.
Contacts Fresenius Medical Care AG & Co.
KGaA
Investor Relations:
Else-Kröner-Straße
1
61346 Bad
Homburg
Germany
+49 (0) 6172
609-0
ir@fmc-ag.com
Contacts CytoSorbents Corp.
Company
Contact:
Amy
Vogel
305 College Road
East
Princeton, NJ
08540
+1 (732)
329-8885
avogel@cytosorbents.com
Public Relations Europe:
Marcus
Schult
kommponisten
+49 69 13823 ext.
960
+49 172
4238938
marcus.schult@die-kommponisten.com
CytoSorbents Europe GmbH:
Josephine Kraus
PA by Dr.
Christian Steiner
+49 30 765 84 66
23
josephine.kraus@cytosorbents.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytosorb-becomes-a-featured-blood-purification-therapy-on-fresenius-medical-care-critical-care-platforms-301598412.html
SOURCE CytoSorbents Corporation; Fresenius Medical Care